Mithramycin
Drug timelines are a Plus or Pro feature.
3 regulatory and trial events tracked for Mithramycin, covering 2016-02-15 to 2022-04-05. Get the full timeline:
Most recent: Clinical Trial Update: Continuous 24h Intravenous Infusion of Mithramycin, an Inhibitor of Cancer Stem Cell Signaling, in People With Primary Thoracic Malignancies or Carcinomas, Sarcomas or Germ Cell Neoplasms With Pleuropulmonary Metastases [Phase 1, Phase 2]